Johnson & Johnson’s RYBREVANT FASPRO Shows Strong HNSCC Results
CHICAGO, Illinois, May 31, 2026 Johnson & Johnson has reported pivotal results from the Phase 1b/2 OrigAMI-4 study, demonstrating...
GRAIL
Advertisement
GRAIL’s Galleri® Test Increases Cancer Detection 6.5-Fold in PATHFINDER 2 Study
MENLO PARK, California, May 31, 2026 GRAIL, Inc. has unveiled compelling new results from its registrational PATHFINDER 2 study,...
Advertisement
